Medical Condition

hematologic malignancy

Total Trials

9

Recruiting Now

9

Trial Phases

Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for hematologic malignancy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hematologic malignancy Clinical Trials

How many clinical trials are currently recruiting for hematologic malignancy?

ClinicalMetric currently tracks 9 actively recruiting clinical trials for hematologic malignancy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 9. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for hematologic malignancy?

hematologic malignancy research spans Phase 1 (4 trials), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a hematologic malignancy clinical trial?

Eligibility criteria for hematologic malignancy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Joshua Sasine, MD, PhD

View Trial →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology

hematologic malignancy

Frequently Asked Questions — hematologic malignancy Clinical Trials

Recruiting Clinical Trials

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Genetics in the Progression of Nephropathies

Early Assessment of Cardiac Function After Treatment With CAR-T Cells

Mosaic Trial for Stem Cell Transplant Recipients

CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies